Geode Capital Management
DNLI icon

Geode Capital Management’s Denali Therapeutics DNLI Stock Holding History

Geode Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Buy
3,973,342
+246,228
+7% +$5.06M 0.01% 1187
2026
Q1 		$71.6M Buy
3,727,114
+268,983
+8% +$5.35M ﹤0.01% 1291
2025
Q4 		$57.1M Sell
3,458,131
-7,926
-0.2% -$134K ﹤0.01% 1398
2025
Q3 		$50.3M Buy
3,466,057
+293,752
+9% +$4.22M ﹤0.01% 1463
2025
Q2 		$44.4M Buy
3,172,305
+135,129
+4% +$1.9M ﹤0.01% 1492
2025
Q1 		$41.3M Buy
3,037,176
+101,893
+3% +$1.95M ﹤0.01% 1495
2024
Q4 		$59.8M Sell
2,935,283
-20,194
-0.7% -$517K ﹤0.01% 1318
2024
Q3 		$86.1M Sell
2,955,477
-27,061
-0.9% -$671K 0.01% 1083
2024
Q2 		$69.3M Buy
2,982,538
+222,905
+8% +$4.28M 0.01% 1146
2024
Q1 		$56.6M Buy
2,759,633
+100,337
+4% +$1.89M 0.01% 1268
2023
Q4 		$57.1M Buy
2,659,296
+127,461
+5% +$2.52M 0.01% 1260
2023
Q3 		$52.2M Buy
2,531,835
+213,538
+9% +$5.42M 0.01% 1211
2023
Q2 		$68.4M Buy
2,318,297
+172,125
+8% +$4.84M 0.01% 1023
2023
Q1 		$49.4M Buy
2,146,172
+96,215
+5% +$2.65M 0.01% 1201
2022
Q4 		$57M Buy
2,049,957
+273,793
+15% +$8.15M 0.01% 1066
2022
Q3 		$54.5M Buy
1,776,164
+69,583
+4% +$2.26M 0.01% 1020
2022
Q2 		$50.2M Buy
1,706,581
+75,634
+5% +$1.98M 0.01% 1116
2022
Q1 		$52.5M Buy
1,630,947
+2,080
+0.1% +$71.6K 0.01% 1223
2021
Q4 		$72.6M Buy
1,628,867
+21,473
+1% +$1.02M 0.01% 1017
2021
Q3 		$81.1M Buy
1,607,394
+90,373
+6% +$5.09M 0.01% 926
2021
Q2 		$119M Buy
1,517,021
+264,189
+21% +$16.3M 0.02% 707
2021
Q1 		$71.5M Buy
1,252,832
+97,930
+8% +$6.56M 0.01% 953
2020
Q4 		$96.7M Buy
1,154,902
+68,773
+6% +$4.16M 0.02% 714
2020
Q3 		$38.9M Buy
1,086,129
+5,179
+0.5% +$156K 0.01% 1060
2020
Q2 		$26.1M Buy
1,080,950
+98,431
+10% +$2.31M 0.01% 1301
2020
Q1 		$17.2M Buy
982,519
+114,901
+13% +$2.4M ﹤0.01% 1405
2019
Q4 		$15.1M Buy
867,618
+24,847
+3% +$414K ﹤0.01% 1735
2019
Q3 		$12.9M Buy
842,771
+19,138
+2% +$366K ﹤0.01% 1756
2019
Q2 		$17.1M Buy
823,633
+49,746
+6% +$1.11M ﹤0.01% 1589
2019
Q1 		$18M Buy
773,887
+63,865
+9% +$1.34M ﹤0.01% 1487
2018
Q4 		$14.7M Buy
710,022
+677
+0.1% +$12.3K ﹤0.01% 1500
2018
Q3 		$15.4M Buy
709,345
+503,195
+244% +$8.32M ﹤0.01% 1600
2018
Q2 		$3.14M Buy
206,150
+58,072
+39% +$1.09M ﹤0.01% 2591
2018
Q1 		$2.92M Buy
+148,078
New +$3.04M ﹤0.01% 2556

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Geode Capital Management's DNLI Position: Q2 2026 in Review

Geode Capital Management increased its Denali Therapeutics (DNLI) stake by 6.6% in Q2 2026, buying an estimated $5.06M and bringing the position to 3,973,342 shares worth $102M. The position accounts for 0.01% of the portfolio, ranked #1187.

Geode Capital Management first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $119M in Q2 2021. 273 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Geode Capital Management held 3,973,342 shares of Denali Therapeutics worth $102M as of Q2 2026.
  • Geode Capital Management bought 246,228 Denali Therapeutics shares in Q2 2026, an estimated $5.06M.
  • Denali Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #1187 holding.
  • Geode Capital Management first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
  • Geode Capital Management's Denali Therapeutics position peaked at $119M in Q2 2021.
  • 273 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.